INC Research Partners with goBalto to Further Enhance Clinical Study Startup Solution
goBalto, Inc., a developer of new-generation web clinical research solutions, today announced that INC Research, a therapeutically-focused clinical research organization (CRO), has selected goBalto Tracker 2.0 as its global site activation solution. Tracker is a secure, web-based platform that enables study teams to track and manage site activation activities in clinical trials.
"We chose goBalto Tracker as part of our study startup solution because it offers enhanced visibility into the traditionally cumbersome process of activating sites for clinical trials," said Alistair Macdonald, Chief Operating Officer at INC Research. "The system creates efficiencies through streamlined communication among sites, sponsors and CROs. This ultimately drives shorter timelines and cost savings for our customers."
Tracker, goBalto's lead product, is a software-as-a-service (SaaS) application that helps small and large clinical research organizations (CROs), pharmaceutical, and medical device companies track multiple studies and keep managers on the same page during the site activation phase of a study. Configurable workflows allow study managers to implement and benchmark processes globally. The application shows real-time status that study managers can use to find process bottlenecks and optimize resources.
Jae Chung, Founding CEO of goBalto, stated "The clinical trial industry recognizes how important it is to get study startup right and INC Research is at the forefront of utilizing technology to benefit their study sponsors in this critical phase. We're very proud that INC Research has selected Tracker as its study startup solution to provide transparency and insight into the site initiation process."
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
